US FDA clears Oxford Biomedica's cancer vaccine TroVax for further development
This article was originally published in Scrip
Executive Summary
The US FDA has given the go-ahead for Oxford Biomedica to resume developing its novel cancer vaccine TroVax in renal cancer, and pursue further indications in multiple metastatic cancer settings, including colorectal, ovarian and triple-negative breast cancers.